Saltar al contenido
MilliporeSigma
Todas las fotos(1)

Key Documents

D6035

Sigma-Aldrich

Disopyramide phosphate salt

Sinónimos:

α-Diisopropylaminoethyl-α-phenylpyridine-2-acetamide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula lineal:
C21H29N3O · H3PO4
Número de CAS:
Peso molecular:
437.47
EC Number:
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

form

solid

SMILES string

OP(O)(O)=O.CC(C)N(CCC(C(N)=O)(c1ccccc1)c2ccccn2)C(C)C

InChI

1S/C21H29N3O.H3O4P/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19;1-5(2,3)4/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25);(H3,1,2,3,4)

InChI key

CGDDQFMPGMYYQP-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Application

Disopyramide phosphate salt has been used as an internal standard for plasma sample analysis by mass spectrometry. It might be used as a test compound in a teratogenicity study.

Biochem/physiol Actions

Disopyramide is found to stabilize the cell membrane by altering the action potential. It might act as an antiarrhythmic agent.
Class IA antiarrhythmic; sodium channel blocker

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

ppe

dust mask type N95 (US), Eyeshields, Gloves


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

0
Drugs for Pregnant and Lactating Women, 252-338 (2009)
Anthony A Fossa et al.
The Journal of pharmacology and experimental therapeutics, 302(2), 828-833 (2002-07-20)
QT interval prolongation of the electrocardiogram has been associated with the occurrence of life-threatening fatal ventricular arrhythmias. To understand the relationship between preclinical cardiac conduction assessment to clinical outcome, comparisons of free (unbound)-plasma drug concentrations and their associated effects in
Shunichiro Sumi et al.
Pacing and clinical electrophysiology : PACE, 33(6), e53-e56 (2010-01-12)
The patient was a 57-year-old man with Brugada syndrome, who had been implanted with a implantable cardioverter defibrillator (ICD). The frequency of ventricular fibrillation (VF) started to increase about 4 years after ICD implantation, occurring, at worst, six times in
Annerie M E Moers et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 14(3), 426-430 (2011-09-22)
Patients undergo ablation for focal atrial fibrillation (AF) as a result of failure of anti-arrhythmic drugs. Our basic studies have implicated cholinergic and adrenergic neurotransmitter release as the underlying mechanism for focal AF. Therefore, we tested the efficacy of a
Aziza El Harchi et al.
Journal of molecular and cellular cardiology, 52(1), 185-195 (2011-10-13)
The Class Ia antiarrhythmic drug disopyramide (DISO) causes QT interval prolongation that is potentially dangerous in acquired Long QT Syndrome but beneficial in short QT syndrome, through inhibition of the hERG-encoded channels responsible for rapid delayed rectifier K(+) current (I(Kr)).

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico